ReviewSmall methods2025
Recent Advances in Nanomedicine-Mediated Abdominal Aortic Aneurysm Treatment.
Review in Small methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MMP-Activated Liposomal Nanoplatform Co-loaded with Kaempferol and ICG for Targeted Imaging and Therapy of Abdominal Aortic Aneurysm.ACS applied materials & interfaces · 2026Article
- The Protective Effect of N, Ce-doped Carbon Dots Against HApplied biochemistry and biotechnology · 2026Article
- Targeted inflammatory microenvironment remodeling and NIR-II photothermal therapy for abdominal aortic aneurysm.Materials today. Bio · 2026Article
- Targeting IL-1β: a potential strategy for alleviating the immunopathology of aortic aneurysms.Frontiers in immunology · 2026Review
- Recent Advances in Nanomedicine-Mediated Abdominal Aortic Aneurysm Treatment.Small methods · 2025Review
- Comparative efficacy of pharmacological agents on abdominal aortic aneurysm growth rate: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Abdominal aortic aneurysm (AAA) is an enlarged area in the lower part of the body's main artery, characterized by complex physiological environments and multi-mechanistic pathogenesis. The continuous growth and the risk of rupture of AAAs threaten patients' health. Despite positive outcomes in preclinical studies, no pharmacological approach is proven effective in stabilizing and reversing the progression in the clinic. Insufficient local drug concentration, dynamic aorta environment, and unique anatomical characteristics attenuate the efficacy of systemic administration. To overcome the gap between laboratory and clinic, nanomedicine strategies are applied in a wide range of studies to optimize the in vivo behavior of the drugs. The emerging nano-delivery technologies are shown to have the potential to improve the efficacy of drugs against AAA through diverse mechanisms. Herein, the composition and characteristics of the AAA environment are summarized, followed by the review of multiple AAA-targeted nano-scale therapeutic strategies, which are classified according to the utilized AAA properties and the targeting mechanism. Additionally, the future of developing novel AAA therapeutic strategies is being envisioned and discussed. These technologies are expected to be the last piece of the puzzle to solve the lack of effective pharmacological methods for treating AAA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.